ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2557

Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades

Mahmut Kaymakci1, Nicholas Boire1, Melanie Bois1, Mohanad Elfishawi1, Hannah Langenfeld2, Andrew Hanson2, Cynthia Crowson1, Matthew Koster1, Cornelia M. Weyand3 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic School of Medicine and Stanford University, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, glucocorticoids, Inflammation, surgery, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed to reflect damage from prior aortitis, however whether ongoing aortic inflammation contributes to aneurysm formation is largely unknown. The aim of this project was to investigate the clinicopathologic findings of patients with GCA who underwent thoracic aorta repair.

Methods: Patients who had thoracic aorta surgery at our institution between January 1, 2000, and December 31, 2021, were identified and screened for a prior diagnosis of GCA. The available data was manually abstracted from the medical records of all study subjects, and two cardiovascular pathologists reviewed available aorta tissue obtained during surgery. Grade 1 inflammation of the aorta was defined as inflammation limited to the peri-vasa vasorum or focal involvement, grade 2 was defined as inflammation beyond the peri-vasa vasorum or multifocal involvement but less than 50% of the medial thickness, grade 3 was defined as diffuse inflammation with involvement of equal or more than 50% of the medial thickness. Survival rates were estimated using Kaplan-Meier methods. Overall observed survival was compared with lifetable rates from the US population. The standardized mortality ratio was estimated as the ratio of the observed and expected number of deaths.

Results: Of the 4621 patients who underwent thoracic aorta surgery during the study period, 49 had a previous diagnosis of GCA (Table 1). Thirty-two (65%) were female, and 43 (88%) patients had either positive temporal artery biopsy or met the 1990 ACR or 2022 ACR/EULAR classification criteria for GCA. Forty-one patients had cranial symptoms at GCA diagnosis. All patients were considered in clinical remission at the time of aortic surgery. Ten (20%) patients had thoracic aortic dissection. Inflammatory markers (median [IQR]) were lower at the time of aortic surgery compared to initial diagnosis (erythrocyte sedimentation rate (mm/hr): 91 [54.0- 109.5] vs. 10 [5.0- 20.0]; C-reactive protein (mg/L): 76.5 [28.0- 139.0] vs. 3.1 [3.0- 8.0]). Histopathologic evaluation of the aortic tissue revealed active aortitis in most patients with GCA (40/49, 82%) after a median (IQR) of 6.0 (2.6- 10.3) years from GCA diagnosis. Healed aortitis was detected in 5 (10%) patients, and in 4 (8%) patients there was no evidence of active or healed aortitis. Nineteen (39%) patients were on immunosuppressive treatment at the time of aortic surgery. The detailed histopathologic re-evaluation of 43 out of 49 aortic samples revealed grade 1 aortitis in 17 (40%) patients, grade 2 in 12 (28%), and grade 3 in 5 (12%) (Table 2). The overall mortality compared to age and sex-matched general population was significantly increased with a standardized mortality ratio of 1.55 (95% CI, 1.05- 2.19) (Figure 1).

Conclusion: Histopathologic evaluation of the thoracic aorta obtained during surgery revealed active aortitis in most patients with GCA despite being considered in clinical remission several years after the initial diagnosis. Chronic, smoldering aortic inflammation likely contributes to the development of aortic aneurysm and dissection in GCA.

Supporting image 1

Table 1. Characteristics of the patients with giant cell arteritis who had thoracic aorta surgery.

Supporting image 2

Table 2. Detailed histopathologic re-evaluation of 34 aorta specimens showing active aortitis.

Supporting image 3

Figure 1. Overall survival of the patients with giant cell arteritis compared to expected rates from United States total lifetables (observed: solid blue line; expected: dashed red line).


Disclosures: M. Kaymakci: None; N. Boire: None; M. Bois: None; M. Elfishawi: None; H. Langenfeld: None; A. Hanson: None; C. Crowson: None; M. Koster: None; C. Weyand: None; K. Warrington: Bristol-Myers Squibb(BMS), 5, Chemocentryx, 1, 6, Eli Lilly, 5, kiniksa, 5.

To cite this abstract in AMA style:

Kaymakci M, Boire N, Bois M, Elfishawi M, Langenfeld H, Hanson A, Crowson C, Koster M, Weyand C, Warrington K. Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinicopathologic-features-of-patients-with-giant-cell-arteritis-and-thoracic-aorta-repair-a-single-center-experience-over-two-decades/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinicopathologic-features-of-patients-with-giant-cell-arteritis-and-thoracic-aorta-repair-a-single-center-experience-over-two-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology